Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

Yvette Drew; J Ledermann; G Hall; D Rea; R Glasspool; M Highley; Gordon Jayson; J Sludden; J Murray; D Jamieson; S Halford; G Acton; Z Blackholer; R Mangano; A Boddy; N Curtin; R Plummer

doi:10.1038/bjc.2016.41

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

Yvette Drew, J Ledermann, G Hall, D Rea, R Glasspool, M Highley, Gordon Jayson, J Sludden, J Murray, D Jamieson, S Halford, G Acton, Z Blackholer, R Mangano, A Boddy, N Curtin, R Plummer

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Article › peer-review

Original language	English
Article number	e21
Journal	Br J Cancer
Volume	114
Early online date	22 Mar 2016
DOIs	https://doi.org/10.1038/bjc.2016.41
Publication status	Published - 2016

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/bjc.2016.41Licence: CC BY

http://10.1038/bjc.2016.133Licence: CC BY

Cite this

Drew, Y., Ledermann, J., Hall, G., Rea, D., Glasspool, R., Highley, M., Jayson, G., Sludden, J., Murray, J., Jamieson, D., Halford, S., Acton, G., Blackholer, Z., Mangano, R., Boddy, A., Curtin, N., & Plummer, R. (2016). Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. Br J Cancer, 114, Article e21. https://doi.org/10.1038/bjc.2016.41

@article{24c09b6b2b0542e6876bac7a8d790f43,

title = "Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer",

author = "Yvette Drew and J Ledermann and G Hall and D Rea and R Glasspool and M Highley and Gordon Jayson and J Sludden and J Murray and D Jamieson and S Halford and G Acton and Z Blackholer and R Mangano and A Boddy and N Curtin and R Plummer",

year = "2016",

doi = "10.1038/bjc.2016.41",

language = "English",

volume = "114",

journal = "Br J Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

}

Drew, Y, Ledermann, J, Hall, G, Rea, D, Glasspool, R, Highley, M, Jayson, G, Sludden, J, Murray, J, Jamieson, D, Halford, S, Acton, G, Blackholer, Z, Mangano, R, Boddy, A, Curtin, N & Plummer, R 2016, 'Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer', Br J Cancer, vol. 114, e21. https://doi.org/10.1038/bjc.2016.41

TY - JOUR

T1 - Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

AU - Drew, Yvette

AU - Ledermann, J

AU - Hall, G

AU - Rea, D

AU - Glasspool, R

AU - Highley, M

AU - Jayson, Gordon

AU - Sludden, J

AU - Murray, J

AU - Jamieson, D

AU - Halford, S

AU - Acton, G

AU - Blackholer, Z

AU - Mangano, R

AU - Boddy, A

AU - Curtin, N

AU - Plummer, R

PY - 2016

Y1 - 2016

U2 - 10.1038/bjc.2016.41

DO - 10.1038/bjc.2016.41

M3 - Article

SN - 0007-0920

VL - 114

JO - Br J Cancer

JF - Br J Cancer

M1 - e21

ER -